Indication
Klebsiella pneumonia
Klebsiella pneumonia is an acute lower respiratory tract infection caused by the Gram-negative, encapsulated bacterium *Klebsiella pneumoniae*. Read more about Klebsiella pneumonia
346 drugs 124 manufacturers
Drugs that treat it
Common Klebsiella pneumonia therapies.
MOXIFLOXACIN HCL
LEVOFLOXACIN
CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonKlebsiella pneumonia is an acute lower respiratory tract infection caused by the Gram-negative, encapsulated bacterium *Klebsiella pneumoniae*.
It predominantly affects the pulmonary parenchyma and alveolar spaces, most commonly occurring as a hospital-acquired infection in hospitalized or mechanically ventilated patients, but also presenting in individuals with underlying comorbidities such as alcohol use disorder, chronic lung disease, or diabetes mellitus.
Pathophysiologically, the organism's thick polysaccharide capsule impairs phagocytosis, frequently leading to severe necrotizing inflammation, microabscess formation, lung cavitation, and characteristic production of thick, blood-tinged "currant jelly" sputum.
Clinically, it manifests with high fevers, productive cough, pleuritic chest pain, and dyspnea, carrying a substantial risk of rapid progression to bacteremia, respiratory failure, and sepsis.
- nih.gov
Klebsiella pneumonia is an acute lower respiratory tract infection caused by the Gram-negative, encapsulated bacterium *Klebsiella pneumoniae* It predominantly affects the pulmonary parenchyma and alveolar spaces, most commonly occurring as a hospital-acquired infection in hospitalized or mechanically ventilated patients, but also presenting in individuals with underlying comorbidities such as alcohol use disorder, chronic lung disease, or diabetes mellitus Pathophysiologically, the organism's t...
- nih.gov
It predominantly affects the pulmonary parenchyma and alveolar spaces, most commonly occurring as a hospital-acquired infection in hospitalized or mechanically ventilated patients, but also presenting in individuals with underlying comorbidities such as alcohol use disorder, chronic lung disease, or diabetes mellitus
- cdc.gov
It predominantly affects the pulmonary parenchyma and alveolar spaces, most commonly occurring as a hospital-acquired infection in hospitalized or mechanically ventilated patients, but also presenting in individuals with underlying comorbidities such as alcohol use disorder, chronic lung disease, or diabetes mellitus
- nih.gov
Pathophysiologically, the organism's thick polysaccharide capsule impairs phagocytosis, frequently leading to severe necrotizing inflammation, microabscess formation, lung cavitation, and characteristic production of thick, blood-tinged "currant jelly" sputum
- nih.gov
Pathophysiologically, the organism's thick polysaccharide capsule impairs phagocytosis, frequently leading to severe necrotizing inflammation, microabscess formation, lung cavitation, and characteristic production of thick, blood-tinged "currant jelly" sputum
- nih.gov
Clinically, it manifests with high fevers, productive cough, pleuritic chest pain, and dyspnea, carrying a substantial risk of rapid progression to bacteremia, respiratory failure, and sepsis
Personalize your experience
Follow Klebsiella pneumonia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.